Perkütan Koroner İşlem Sonrası Zayıf TIMI Akımı Olan ST Elevasyonlu Miyokart İnfarktüsü Hastalarında Soluble ST2 ve N Terminal-Pro Brain Natriüretik Peptid Kombinasyonunun Kısa Dönem Mortaliteyi Öngördürebilirlik Değeri

Abstract

Giriş: ST elevasyonlu miyokart infarktüsü (STEMİ)’nde, soluble ST2 (sST2) ve N Terminal-Pro Brain Natriüretik Peptid (NT-proBNP) seviyelerindeki yükselme net olarak ortaya konmakla birlikte, STEMİ hastalarında, özellikle de başarısız perkütan koroner işlem (PKİ) uygulananlarda, sST2 ve NT-proBNP’nin kombinasyonunun prognostik değerine ait veriler kısıtlıdır. Bu çalışmada, işlem sonrası TIMI akımı düşük olan STEMİ hastalarında sST2 ve NT-proBNP kombinasyonunun kısa dönem mortaliteyi öngördürmesi açısından klinik önemini değerlendirmeyi amaçladık. Hastalar ve Yöntem: İşlem sonrası düşük TIMI akımı olan 104 hasta çalışmaya dahil edildi. TIMI 3 akım sağlanamaması, işlem sonrası düşük TIMI akım olarak kabul edildi. Çalışma popülasyonu sST2 ve NT-proBNP seviyelerine göre gruplara ayrıldı. Kısa dönem mortalitenin bağımsız prediktörleri araştırıldı. Bulgular: Otuz günlük mortalite 15 (%14.4) hastada gerçekleşti. Mortalite gerçekleşen hastalarda sST2 (46.9 ± 23.8 ng/mL vs. 32.5 ± 12.0 ng/mL, p= 0.001) ve NT-proBNP (2387.2 ± 2255.5 pg/mL vs. 1217.1 ± 1588.8 pg/mL, p= 0.015) seviyeleri daha yüksekti. Multivaryant regresyon analizi, yüksek serum sST2’nin (odds oranı 5,024, %95 CI 1.132-22.308, p= 0.034) kısa dönem mortaliteyi bağımsız olarak predikte edebildiğini, fakat aynı durumun NT-proBNP için geçerli olmadığını gösterdi (odds oranı 4.059, %95 CI 0.894-18.427, p= 0.070). Buna ek olarak, yüksek sST2 seviyeleri, yüksek NT-proBNP ile kombine edildiğinde 30 günlük mortalite için en yüksek odds oranına ulaşıldı (13.02, %95 CI 5.41-31.23, p< 0.001). Sonuç: Bu sonuçlar, sST2 ve NT-proBNP kombinasyonunun, işlem sonrası düşük TIMI akım olan STEMİ hastalarında kısa dönem mortalitenin önemli bir prediktörü olduğunu ortaya koymaktadır.

Keywords

• Beyin natriüretik peptid,no-reflov fenomeni,mortalite,perkütan koroner girişim

The Predictive Value of the Combination of Soluble ST2 and N Terminal-Pro Brain Natriuretic Peptide for Short-Term Mortality in ST-Elevation Myocardial Infarction Patients with Poor PostProcedural TIMI Flow

Abstract

Introduction: The increase in soluble ST2 (sST2) and N Terminal-Pro Brain Natriuretic Peptide (NT-proBNP) in ST-elevation myocardial infarction (STEMI) is well established, however, the existing data regarding the combination of sST2 and NT-proBNP values as prognostic markers after STEMI are limited, particularly in the case of those with failed percutaneous coronary intervention (PCI). This study aimed to assess the clinical significance of the sST2 and NT-proBNP combination in predicting short-term mortality in STEMI patients with post-procedural poor thrombolysis in myocardial infarction (TIMI) flow. Patients and Methods: A total of 104 patients with post-procedural poor TIMI flow were included in the study. Failure to provide a 3 flow grade was accepted as post-procedural poor TIMI flow. The study population was grouped according to the sST2 and NT-proBNP levels. Independent predictors of short-term mortality were investigated. Results: A 30 day mortality was observed in 15 (14.4%) patients. sST2 (46.9 ± 23.8 ng/mL vs. 32.5 ± 12.0 ng/ mL, p= 0.001) and NT-proBNP (2387.2 ± 2255.5 pg/mL vs. 1217.1 ± 1588.8 pg/mL, p= 0.015) levels were higher in patients with mortality. Multivariate regression analysis concluded that high serum sST2 (OR: 5.024, 95% CI 1.132-22.308, p= 0.034) independently predicted short-term mortality, while NT-proBNP did not (OR: 4.059, 95% CI 0.894-18.427, p= 0.070). Furthermore, when a high sST2 level was combined with a high NT-proBNP level, the odds ratio of the 30-day mortality was found to be the highest (13.02, 95% CI 5.41-31.23, p< 0.001). Conclusion: These results suggest that the combined sST2 and NT-proBNP level are essential predictors of short-term mortality in STEMI patients with post-procedural poor TIMI flow.

Keywords

• Brain natriuretic peptide,no-reflow phenomenon,mortality,percutaneous coronary intervention

References

1. 1. Gaziano JM. Global burden of cardiovascular disease. In: Braunwald E, Zipes DP, Libby P (eds). Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia: WB Saunders Company, 2001:1-17.
2. 2. The GUSTO Angiographic Investigators. The effect of tissue plasminogenactivator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
3. 3. Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2010;55:2383-9.
4. 4. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003;145:42-6.
5. 5. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012;58:257-66.
6. 6. Pascual-Figal DA, Januzzi JL. The biology of ST2: the international ST2 consensus panel. Am J Cardiol 2015 Apr 2;115(7 Suppl):3B-7B
7. 7. Lepojaervi ES, Piira OP, Paeaekkoe E, Lammentausta E, Risteli J, Miettinen JA, et al. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left ventricular diastolic filling properties. Front Physiol 2015;6:200.
8. 8. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarctionthrough ST2 signaling. Circ Heart Fail 2009;2:684-91.

9. 9. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259-67.
10. 10. Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010;159:788-94.
11. 11. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936-44.
12. 12. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in myocardial infarction (TIMI) trial. Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-54.
13. 13. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967;20:457-64.
14. 14. Hildebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, Gustafsson F, et al. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J 2010;31:1881-9.
15. 15. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011;4:180-7.
16. 16. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002;39:591-7.
17. 17. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin 1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-6.
18. 18. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827-40.
19. 19. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-90.
20. 20. Jenkins WS, Roger VL, Jaffe AS, Weston SA, AbouEzzeddine OF, Jiang R, et al. Prognostic value of soluble ST2 after myocardial infarction: a community perspective. Am J Med 2017;130:1112.e9-1112.e15.
21. 21. O’ Donoghue ML, Morrow DA, Cannon CP, Jarolim P, Desai NR, Sherwood MW, et al. Multimarker risk stratification in patients with acute myocardial infarction. J Am Heart Assoc 2016;5.
22. 22. Liu X, Hu Y, Huang W, Zhang G, Cao S, Yan X, et al. Soluble ST2 for prediction of clinical outcomes in patients with ST-segment elevation myocardial infarction receiving primary PCI. Int Heart J 2019;60:19-26.
23. 23. Kontos MC, Lanfear DE, Gosch K, Daugherty SL, Heidenriech P, Spertus JA. Prognostic value of serial N-terminal pro-brain natriuretic peptide testing in patients with acute myocardial infarction. Am J Cardiol 2017;120:181-5.
24. 24. Yu J, Oh PC, Kim M, Moon J, Park YM, Lee K, et al. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP. PLoS One 2017;12:e0182829.
25. 25. Tolppanen H, Rivas-Lasarte M, Lassus J, Sadoune M, Gayat E, Pulkki K, et al. Card shock investigators. Combined measurement of soluble ST2 and amino-terminal Pro-B type natriuretic peptide provides early assessment of severity in cardiogenic shock complicating acute coronary syndrome. Crit Care Med 2017;45:e666-e673.
26. 26. Barbarash O, Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Akbasheva O, et al. Prognostic value of soluble ST2 during hospitalization for ST-segment elevation myocardial infarction. Ann Lab Med 2016;36:313-9.
27. 27. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.